Pharma BD Deal Intelligence

Merck & Co. Inc. / Imago BioSciences Inc.

2022 · Acquisition/Merger · $1.4B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Merck acquired Imago BioSciences for approximately $1.35 billion ($36.00 per share) in an all-cash tender offer, gaining bomedemstat, an oral LSD1 inhibitor in clinical development for myeloproliferative neoplasms including myelofibrosis.

Key facts

Announced Nov 21, 2022
Closed Jan 11, 2023
Deal value $1.4B
Deal type Acquisition/Merger
Therapeutic area Hematology, Neurology, Oncology
Indications Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Key assets bomedemstat (IMG-7289)
Mechanism LSD1 (lysine-specific demethylase 1) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals